Cutia Therapeutics
2487.HK News Today: Stay Updated with the Latest Cutia Therapeutics News in Real Time
Find 2487.HK news now at Meyka AI. Stay informed with the latest Cutia Therapeutics stocks updates, including price news, market analysis, and expert insights.
IMMX Maintained at Buy by H.C. Wainwright, May 2026
H.C. Wainwright maintains Buy rating on IMMX, raises price target to $20 from $15 on May 22, 2026.
XOMA Downgraded to Hold from Buy at Benchmark May 22
Benchmark downgraded XOMA to Hold from Buy on May 22, 2026. Stock trades at $41.65 with mixed analyst sentiment.
ROIV Maintained at Overweight by Piper Sandler, May 2026
Piper Sandler maintains Roivant Sciences (ROIV) at Overweight rating, citing mosliciguat Phase 2 catalysts and 2026 pipeline strength.
UTHR Maintained at Buy by Cowen & Co., May 2026
Cowen & Co. maintains Buy rating on United Therapeutics (UTHR) as a top biotech idea with strong fundamentals.
UTHR Stock: Officer Paul Mahon Sells 8,300 Shares May 22, 2026
United Therapeutics EVP Paul Mahon sold 8,300 stock options for $1.21M on May 21, 2026. Latest insider trading activity.
MindMaze Therapeutics Holding Surges 13.8% on Biotech Recovery
MMTX.SW stock jumps 13.8% to CHF0.4895 on SIX. MindMaze Therapeutics gains momentum in digital therapeutics sector.
Zelira Therapeutics Limited (ZLD.AX) Holds A$0.50 as Biotech Sector Stabilizes
ZLD.AX stock trades at A$0.50 on ASX. Zelira Therapeutics holds steady as cannabinoid biotech faces structural headwinds.
Relief Therapeutics Holding AG Bounces 0.87% as Clinical Pipeline Gains Traction
RLF.SW stock rises 0.87% pre-market. Relief Therapeutics advances Phase 3 respiratory trials and multiple clinical programs in rare disease focus.
Kinarus Therapeutics Holding AG (PRFN.SW) Drops 8.1% on Clinical-Stage Pressure
PRFN.SW stock falls 8.1% to CHF0.0362 on SIX. Kinarus Therapeutics faces clinical-stage headwinds with KIN001 development ongoing.